EP3753939A1 — Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
Assigned to Array Biopharma Inc · Expires 2020-12-23 · 5y expired
What this patent protects
Provided herein are compounds of the Formula I:and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X<sup>1</sup>, X<sup>2</sup>, X<sup>3</sup>, X<sup>4</sup>, Ring D, and E have the meanings g…
USPTO Abstract
Provided herein are compounds of the Formula I:and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X<sup>1</sup>, X<sup>2</sup>, X<sup>3</sup>, X<sup>4</sup>, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
Drugs covered by this patent
- Retevmo (SELPERCATINIB) · Eli Lilly
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.